Current Opinion in Hematology:
MYELOID BIOLOGY: Edited by David C. Dale
Inhibitors of CXC chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases
Hummel, Stephaniea,b; Van Aken, Hugoa; Zarbock, Alexandera,b
aDepartment of Anesthesiology, Intensive Care and Pain Medicine, University of Muenster
bMax-Plank Institute Muenster, Muenster, Germany
Correspondence to Alexander Zarbock, MD, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149 Muenster, Germany. Tel: +49 251 83 47252; fax: +49 251 88704; e-mail: firstname.lastname@example.org
Purpose of review: The CXC chemokine receptor type 4 (CXCR4), which is a G-protein coupled receptor, and its ligand CXCL12 play an important role in neutrophil homeostasis and inflammation. This review focuses on involvement of the CXCL12/CXCR4 axis in inflammation and different inflammatory diseases and depicts that blocking CXCR4 is an attractive therapeutic strategy.
Recent findings: Binding of CXCL12 to CXCR4 retains immature neutrophils in the bone marrow and also participates in leukocyte recruitment into inflamed tissue. The CXCL12/CXCR4 axis is also involved in several inflammatory processes and diseases including the WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome, HIV, autoimmune disorders, ischemic injury, and pulmonary fibrosis.
Summary: Based on these findings, blocking CXCR4 seems to be a therapeutic strategy in inflammatory diseases. Several promising CXCR4 antagonists are in different stages of development and clinical trials. Currently, only plerixafor (AMD3100) has been approved for short-term application.
Neutrophils constitute the first line of host defense during infection and inflammation. By elimination of pathogens, they represent a major component of the innate immune response . They are produced in the bone marrow and after maturation, they are released into the circulation [2–4]. Homeostasis is regulated by a balance of neutrophil production, release from the bone marrow, and clearance from the circulation . Neutrophils are characterized by a circulating half-life of 6–8 h and are produced at a rate of 5 × 1010–10 × 1010 cells/day by the bone marrow . Less than 2% of the total body of mature neutrophils is circulating under basal conditions .
Recruitment of leukocytes into inflamed tissue in response to infection or stress is crucial for host defense . During the interaction with endothelial cells, neutrophils are exposed to chemokines and selectins, which induce integrin activation and neutrophil recruitment . Chemokines are a family of small secreted cytokines and play a crucial role in leukocyte activation and trafficking into inflamed tissue through interacting with G-protein coupled receptors (GPCRs), which are expressed on the surfaces of their target cells [9–11]. The activation of GPCRs leads to an activation of a signaling cascade, which ultimately leads to integrin activation [12▪▪]. Activated integrins can subsequently bind to their counter-receptors on endothelial cells and mediate slow rolling, adhesion, and transmigration [13,14].
Chemokines can be classified into four subfamilies – CXC, CC, C, or CX3C – based on their number and spacing of conserved cysteine residues near the N-terminus [11,15,16]. CXC, CC, and CX3C chemokines have four conserved cysteines, whereas C chemokines have only two. CXC and CX3C chemokines are differentiated by the presence of one (CXC) or three (CX3C) amino acids between the first and the second cysteine. However, the two cysteines of CC chemokines are adjacent. The nomenclature of chemokines is a combination of their subclass followed by ‘L’ for ligand and a specific number [15,17].
THE CXCL12/CXC CHEMOKINE RECEPTOR TYPE 4 AXIS
GPCRs consist of an α-subunit and a βγ-complex, which remain associated to the guanine nucleotide GDP at basal state. CXC chemokine receptor type 4 (CXCR4) is a GPCR belonging to the class I or rhodopsin-like GPCR family [18,19] and is specific for the chemokine CXCL12. CXCR4 is formed by 352 amino acid residues containing an N-terminal domain, seven transmembrane domains, three extracellular loops, three intracellular loops, and a C-terminal domain .
The CXCL12 cDNA clone was first isolated in 1993 by Tashiro et al. from a murine bone marrow stromal cell line . The gene was originally named stromal cell-derived factor-1 (SDF-1). CXCL12 is a homeostatic chemokine and mainly localized in bone marrow stromal cells. Until recently, the role of CXCL12/CXCR4 in inflammatory immune response remained unclear. However, recent studies demonstrated that CXCL12 and CXCR4 participate in tissue infiltration of neutrophils and lymphocytes after inflammatory stimuli [22,23]. Additionally, CXCL12 is a major regulator of hematopoietic cell homing to the bone marrow . Under normal conditions, CXCR4 is mainly expressed in the hematopoietic and immune systems.
CXC CHEMOKINE RECEPTOR TYPE 4-INDUCED SIGNALING
Binding of CXCL12 to CXCR4 induces Gαi-mediated signaling resulting in the activation of Ras/mitogen-activated protein (MAP) kinases, phosphatidylinositol 3-kinase (PI3K), and Akt. These signaling pathways participate in a variety of physiological responses such as chemotaxis, cell survival, proliferation, intracellular calcium flux, and gene transcription (Fig. 1).
Binding of a chemokine to its receptor may induce different cellular responses, including reorganization of the actin cytoskeleton, upregulation, of integrin expression, and integrin activation, adhesion, migration, and chemotaxis . In line with this, CXCL12/CXCR4-induced chemotaxis and neutrophil migration plays a crucial role in inflammatory diseases.
CXCR4-mediated chemotaxis is basically mediated by PI3K [26▪]. Signaling via the PI3K pathway triggers activation of Akt-dependent, PAK-dependent, and Cdc42-dependent pathways involved in cell polarization, actin polymerization, and neutrophil migration [27,28]. The other pathway that is triggered by CXCR4 engagement activates ERK (extracellular signal receptor kinase). ERK translocates to the nucleus and activates several transcription factors and leads to changes in gene expression and cell cycle progression.
ROLE OF CXC CHEMOKINE RECEPTOR TYPE 4 IN NEUTROPHIL HOMEOSTASIS
CXCR4 plays a dual role in neutrophil homeostasis. Under physiological conditions, upregulation of CXCR4 on circulating neutrophils supports homing to the bone marrow, where these cells undergo apoptosis and are phagocytosed by stromal macrophages [29,30]. The numbers of circulating neutrophils are strikingly stable in healthy humans [31,32] and mice . To exit the bone marrow, neutrophils have to migrate across the bone marrow endothelium and pass through cell–cell junctions and cell body of the endothelium [2,34,35]. CXCR4 levels on immature neutrophils are very high, whereas CXCR4 levels on mature neutrophils are low. Interaction of CXCR4 and CXCL12 results in retaining neutrophils within the bone marrow environment. Therefore, mature neutrophils, which express only low levels of CXCR4, can leave the bone marrow and enter the circulation. Different studies showed a cross-talk between CXCR4/CXCL12 and the VLA-4–VCAM-1 axis concerning the retention and release of neutrophils from the bone marrow under homeostatic conditions .
CXCR4-induced homing of neutrophils to the bone marrow stimulates G-CSF (colony stimulating factor) production, which constitutes the homeostatic link between clearance and production/release . G-CSF is a major mobilizing cytokine and a regulator of physical granulopoiesis by increasing the proliferation, differentiation, and survival of neutrophil precursors . Different studies indicated a decreased expression of CXCL12 in the bone marrow and CXCR4 expression on neutrophils by G-CSF treatment [38–40]. These findings suggest that disruption of CXCR4 signaling is the main factor mediating neutrophil release by G-CSF.
A defect in CXCR4 results in WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), which is an immunodeficiency disorder . Myelokathexis refers to the retention of mature neutrophils in the bone marrow, resulting in neutropenia. Most patients with WHIM syndrome are panleukopenic, which is the major cellular mechanism in this described disease . Affected patients show an increased number of neutrophils in the bone marrow, initiated by autosomal dominant inheritance of carboxyl terminal truncation mutations that remove 10–19 amino acids from CXCR4 . This mutation results in an enhanced sensitivity to CXCL12 and promotes abnormal neutrophil retention [44–46]. Deletion of CXCR4 in murine myeloid cells results in neutrophil release into the blood [1,47,48]. Patients with WHIM are treated with G-CSF and intravenous immunoglobulin. However, the treatment strategy has a number of disadvantages including nonspecificity and high cost .
In addition to its crucial roles in neutrophil homeostasis, CXCR4 is associated with the pathophysiology of different inflammatory diseases, including autoimmune diseases, ischemic injuries, and lung diseases. The diverse functions of CXCR4 in inflammation and the discovery of therapeutic strategies during recent years will be highlighted in this review.
CXC CHEMOKINE RECEPTOR TYPE 4 ANTAGONISTS
The three major categories of CXCR4 antagonists under clinical investigation include small peptide antagonists, nonpeptide antagonists, and antibodies. The pivotal role of CXCR4 antagonists in inflammatory diseases (Fig. 2) will be described in more detail in the following sections.
Peptide-based CXCR4 antagonists are derived from naturally occurring substances, including tachyplesin and polyphemusin . Synthetic analogues were subsequently synthesized and some of these, like T140, are unstable in serum. Due to this disadvantage, analogues of T140 were evolved, including TC14012, TN14003, and TZ14001. Preclinical studies demonstrated the ability of TN14003 to prevent metastasis, and improvement of posthematopoietic stem cell (HSC) transplant bone marrow recovery in murine experiments.
The CXCR4 antagonists plerixafor (Mozobil, formerly AMD3100) and AMD3465 belong to the group of nonpeptide antagonists. Both are reversible antagonists of CXCR4, plerixafor being a bicyclam and AMD3465 an N-pyridinylmethylene monocyclam derivate . AMD3100 was first described for its potent activity against HIV infection [52,53]. In an initial (phase I) clinical trial, administration of plerixafor showed leukocytosis and an increased CD34+ HSC count in peripheral blood [54,55]. In a phase II study, the combination of AMD3100 with G-CSF showed a stronger mobilization of CD34+ cells to the circulation than G-CSF alone . Phase III studies in myeloma and non-Hodgkin lymphoma (NHL) patients verified these findings [57,58]. On the basis of these findings, the CXCR4 antagonist plerixafor was approved for clinical use by the European Medicines Agency (EMA) in July 2003 and by the US Food and Drug Administration (FDA) in December 2008.
MDX-1338 (BMS-936564) is a human anti-CXCR4 monoclonal antibody that blocks the binding of CXCL12 to its receptor resulting in a decreased intracellular calcium surge and chemotaxis .
CXC CHEMOKINE RECEPTOR TYPE 4 ANTAGONISTS AND INFLAMMATORY DISEASES
The following sections summarize current knowledge about the CXCL12/CXCR4 axis in inflammatory diseases and discuss its potential as a pharmaceutical target.
Rheumatoid arthritis (RA) is an autoimmune disease, which affects numerous joints in the body. It is characterized by chronic inflammation of multiple joints, proliferation of the synovial cells, and irreversible destruction of the cartilage and bone of the affected joints [60–63]. Due to this reaction, massive infiltration of neutrophils and macrophages to the inflamed joints and the release of pro-inflammatory cytokines (e.g., interleukin-1β and tumor necrosis factor-α) aggravate the inflammation and immune response .
Recently, different studies support the involvement of the CXCL12/CXCR4 axis in memory T-cell migration into the inflamed RA synovium. Nanki et al. observed an increased expression level of CXCR4 in memory T cells and, apart from this, an exceedingly high concentration of CXCL12 in the synovium of RA patients. Furthermore, they could also show that CXCL12 stimulates the migration of the memory T cells and inhibits T-cell apoptosis, which clearly indicates the crucial role of the CXCL12/CXCR4 axis in T-cell accumulation in the RA synovium.
Blocking CXCL12 in a chemotaxis assay of T helper 1 cells toward RA synovial fluid suggests that the CXCL12/CXCR4 axis is important for T helper cell I migration in RA. Studies in which CXCR4 was eliminated or blocked showed a reduced severity of collagen-induced arthritis, without modulating the humoral immunity [66–68]. In addition, Tamamura et al. verified an anti RA-activity of a T140 analogue (4F-benoyl-TN14003) by assessing its effects on humoral and cellular immunity. This described CXCR4 antagonist inhibits CXCL12-mediated migration of memory T cells. In addition to these, several other CXCR4 antagonists including T140 and T22 are known to reduce the activity of RA [69,70].
Inflammatory bowel disease
An increasing number of studies have demonstrated that the development of the gut immune system is decisively influenced by the intestinal microbiota leading to the generation of immune homeostasis or the development of inflammatory bowel disease (IBD) . IBD, comprising Crohn's disease and ulcerative colitis, is a chronic inflammatory disease of the gastrointestinal tract with relapsing and remitting conditions. It is known that CD4+ T cells have crucial roles in the pathophysiology of IBD. The expression of chemokines and adhesion molecules on cells of the intestinal tissue regulate the recruitment of these immune cells. Therefore, regulation of the migration of leukocytes into the intestinal tissue illustrates a putative therapeutic option for patients with IBD.
The role of the CXCR4/CXCL12 axis in IBD has received very little attention. Nevertheless, Mikami et al. demonstrated a correlation between the activity of ulcerative colitis and the expression levels of CXCR4 on T cells. Further studies reported an expression of CXCR4 by intestinal epithelial cells and lamina propria cells, whereby CXCR4-positive cells in lamina propria are increased in IBD . The same group reported a stronger expression level of CXCL12 in intestinal tissues of ulcerative colitis patients than in those with Crohn's disease. Due to these findings, the CXCR4/CXCL12 axis seems specifically involved in the pathophysiology of ulcerative colitis.
Next, it is interesting to know whether blocking of the CXCL12/CXCR4 axis presents a new therapy option for patients with IBD. Administration of a CXCR4 inhibitor, TF14016, reduced colonic inflammation in a dextran sodium sulfate-induced colitis model . One explanation for the reduced inflammation could be that blocking of CXCR4 inhibits the production of pro-inflammatory cytokines .
Coronary artery and peripheral artery disease have a high incidence of morbidity and mortality . During the acute phase of ischemia, different factors, including hypoxia, oxidative stress, and inflammation, induce tissue damage [76,77]. In response to ischemia, neoangiogenesis and neovascularization are stimulated to restore organ function [78–81]. Regeneration is mediated by soluble factors, including CXCL12 and G-CSF, released by the ischemic tissues. This signaling results in CXCL12/CXCR4-dependent mobilization of progenitor cells (PGCs) from the bone marrow into the circulation and their migration into the injured tissue [82▪▪,83]. After injury, CXCL12 expression levels in the injured tissue increase inducing recruitment of CXCR4-expressing PGCs into the tissue [82▪▪,83].
Furthermore, inhibiting CXCR4 induces PGC mobilization from the bone marrow to the peripheral blood . Studies demonstrated that the blockade of CXCR4 leads to the mobilization of bone marrow progenitors from the bone marrow after ischemia/reperfusion injury and that this leads to an improved myocardial recovery [85▪▪,86▪▪].
Apart from the administration of AMD3100 for myocardial recovery, long-term treatment in mice alters fracture repair . Fracture repair is mediated by stem and PGC migration, homing, and differentiation. The reported results verified the impairment of fracture healing by inhibiting the recruitment and differentiation of osteo-chondrogenic, endothelial, and hematopoietic progenitors .
The presence of fibrocytes in blood and tissue is a characteristic of chronic lung diseases, including asthma, pulmonary hypertension, and pulmonary fibrosis . Fibrocytes are bone marrow-derived mesenchymal cell precursors, with monocyte morphology, expressing surface markers of leukocytes and HSCs, but also collagen I.
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease of the lungs. It is characterized by the proliferation of fibroblasts and deposition of extracellular matrix [89–91]. A number of studies demonstrated that the entering of bone marrow-derived circulating fibrocytes into injured tissues results in wound healing and fibrosis [92,93]. The CXCL12/CXCR4 axis represents the main pathway in regulation of fibrocyte migration in vitro and in vivo[94,95]. CXCR4-positive fibrocytes have been positively identified in the lung tissue of patients with IPF . Increased levels of CXCL12 in the lung and plasma of patients with IPF correlate with numbers of circulating fibrocytes, which was previously also found in animals [95,97]. The mobilization of circulatory fibrocytes and bone marrow-derived PGCs into injured lungs is controlled by the CXCL12/CXCR4 axis promoting the pathogenesis of pulmonary fibrosis [94,95].
Plerixafor prevents pulmonary fibrosis in bleomycin-induced pulmonary fibrosis in the murine system by inhibiting the recruitment of CD45+, CXCR4+, and collagen I+ fibrocytes into the injured lungs . In another study, the application of AMD3100 in bleomycin-induced lung injury only inhibited fibrocyte recruitment to the lung partially, suggesting that other chemokines may contribute to the migration of fibrocytes into the lung in vivo[99▪].
Recent studies have demonstrated the role of the CXCL12/CXCR4 axis in human diseases, including cancer, inflammation, and autoimmune diseases. As CXCR4 and its ligand CXCL12 have a pivotal role in different diseases, blocking this axis offers an attractive therapeutic option. However, further research is needed to investigate the effects of the blockade of CXCR4 in different inflammatory diseases. This is very important as the blockade of CXCR4 could also lead to a compromised elimination of invading pathogens. Currently, only plerixafor (AMD3100) is approved by the FDA for HSC mobilization. However, no approval exists for inflammatory diseases. Further studies and investigations are required to clarify the specific effect of CXCR4 antagonists in the wide range of inflammatory disease patterns.
The present work was supported by grants from the German Research Foundation (AZ 428/6-1 SFB and 1009/A5 to A.Z.).
Conflicts of interest
There are no conflicts of interest.
REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as:
▪ of special interest
▪▪ of outstanding interest
1. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 2009; 113:4711–4719.
2. Burdon PC, Martin C, Rankin SM. Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR + CXC chemokines. Br J Haematol 2008; 142:100–108.
3. Inoue S, Osmond DG. Basement membrane of mouse bone marrow sinusoids shows distinctive structure and proteoglycan composition: a high resolution ultrastructural study. Anat Rec 2001; 264:294–304.
4. Petrides PE, Dittmann KH. How do normal and leukemic white blood cells egress from the bone marrow? Morphological facts and biochemical riddles. Blut 1990; 61:3–13.
5. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol 2007; 14:3–8.
6. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol 2010; 31:318–324.
7. Semerad CL, Liu F, Gregory AD, et al. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17:413–423.
8. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678–689.
9. Butcher EC, Williams M, Youngman K, et al. Lymphocyte trafficking and regional immunity. Adv Immunol 1999; 72:209–253.
10. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12:336–341.
11. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121–127.
12▪▪. Herter J, Zarbock A. Integrin regulation during leukocyte recruitment. J Immunol 2013; 190:4451–4457.
In this review, different signaling pathways leading to the change of integrin adhesiveness in neutrophils, monocytes, and lymphocytes are described. Crucial steps of the leukocyte recruitment cascade, including rolling, adhesion, postadhesion strengthening, intravascular crawling, and transmigration, are highlighted.
13. Zarbock A, Ley K. Neutrophil adhesion and activation under flow. Microcirculation 2009; 16:31–42.
14. Yago T, Shao B, Miner JJ, et al. E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin alphaLbeta2-mediated slow leukocyte rolling. Blood 2010; 116:485–494.
15. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005; 280:35760–35766.
16. Mellado M, Rodriguez-Frade JM, Manes S, Martinez AC. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 2001; 19:397–421.
17. Murphy PM, Baggiolini M, Charo IF, et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52:145–176.
18. Zhan W, Liang Z, Zhu A, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem 2007; 50:5655–5664.
19. Lefrancois M, Lefebvre MR, Saint-Onge G, et al. Agonists for the chemokine receptor CXCR4. ACS Med Chem Lett 2011; 2:597–602.
20. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330:1066–1071.
21. Tashiro K, Tada H, Heilker R, et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993; 261:600–603.
22. Wald O, Pappo O, Safadi R, et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004; 34:1164–1174.
23. Ding Z, Jia SH, Marshall JC, et al. Up-regulation of functional CXCR4 expression on human lymphocytes in sepsis. Crit Care Med 2006; 34:3011–3017.
24. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005; 106:1901–1910.
25. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565–568.
26▪. Choi WT, Duggineni S, Xu Y, et al. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem 2012; 55:977–994.
This study describes the pivotal role of CXCR4 and its antagonists in autoimmune diseases, including RA. The authors illustrate important aspects and perspectives in drug discovery research targeting CXCR4.
27. Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 2013; 105:393–404.
28. Servant G, Weiner OD, Herzmark P, et al. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science 2000; 287:1037–1040.
29. Martin C, Burdon PC, Bridger G, et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003; 19:583–593.
30. Nagase H, Miyamasu M, Yamaguchi M, et al. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. J Leukoc Biol 2002; 71:711–717.
31. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146:486–492.
32. Ruggiero C, Metter EJ, Cherubini A, et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 2007; 49:1841–1850.
33. Peters LL, Cheever EM, Ellis HR, et al. Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice. Physiol Genomics 2002; 11:185–193.
34. Campbell FR. Ultrastructural studies of transmural migration of blood cells in the bone marrow of rats, mice and guinea pigs. Am J Anat 1972; 135:521–535.
35. Weiss L. Transmural cellular passage in vascular sinuses of rat bone marrow. Blood 1970; 36:189–208.
36. Petty JM, Lenox CC, Weiss DJ, et al. Crosstalk between CXCR4/stromal derived factor-1 and VLA-4/VCAM-1 pathways regulates neutrophil retention in the bone marrow. J Immunol 2009; 182:604–612.
37. Metcalf D. Hematopoietic cytokines. Blood 2008; 111:485–491.
38. Kim HK, De La Luz Sierra M, Williams CK, et al. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006; 108:812–820.
39. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104:65–72.
40. Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106:3020–3027.
41. Zuelzer WW. Myelokathexis: a new form of chronic granulocytopenia. Report of a case. N Engl J Med 1964; 270:699–704.
42. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011; 118:4957–4962.
43. Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34:70–74.
44. Gulino AV, Moratto D, Sozzani S, et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 2004; 104:444–452.
45. Kawai T, Choi U, Cardwell L, et al. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. Blood 2007; 109:78–84.
46. Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005; 105:2449–2457.
47. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10:463–471.
48. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393:595–599.
49. Kawai T, Malech HL. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 2009; 16:20–26.
50. Nakashima H, Masuda M, Murakami T, et al. Antihuman immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 1992; 36:1249–1255.
51. Sison EA, Brown P. The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol 2011; 4:271–283.
52. De Clercq E, Yamamoto N, Pauwels R, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A 1992; 89:5286–5290.
53. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38:668–674.
54. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44:1667–1673.
55. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102:2728–2730.
56. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:1867–1874.
57. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4767–4773.
58. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720–5726.
59. Kuhne MR, Mulvey T, Belanger B, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 2013; 19:357–366.
60. Kohem CL, Brezinschek RI, Wisbey H, et al. Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:844–854.
61. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 2001; 15:805–829.
62. Morimoto C, Romain PL, Fox DA, et al. Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases. Am J Med 1988; 84:817–825.
63. Morita Y, Yamamura M, Kawashima M, et al. Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 1998; 41:1669–1676.
64. Eck SM, Blackburn JS, Schmucker AC, et al. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun 2009; 33:214–221.
65. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000; 165:6590–6598.
66. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010; 128:509–518.
67. Chung SH, Seki K, Choi BI, et al. CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis. Arthritis Res Ther 2010; 12:R188.
68. Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167:4686–4692.
69. Tamamura H, Fujisawa M, Hiramatsu K, et al. Identification of a CXCR4 antagonist, a T140 analog, as an antirheumatoid arthritis agent. FEBS Lett 2004; 569:99–104.
70. Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets 2005; 9:1267–1282.
71. Hummel S, Veltman K, Cichon C, et al. Differential targeting of the E-Cadherin/beta-Catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function. Appl Environ Microbiol 2012; 78:1140–1147.
72. Mikami S, Nakase H, Yamamoto S, et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther 2008; 327:383–392.
73. Dotan I, Werner L, Vigodman S, et al. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16:583–592.
74. Xia XM, Wang FY, Zhou J, et al. CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. PLoS One 2011; 6:e27282.
75. Cencioni C, Capogrossi MC, Napolitano M. The SDF-1/CXCR4 axis in stem cell preconditioning. Cardiovasc Res 2012; 94:400–407.
76. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000; 106:809–812.
77. Williams RS, Benjamin IJ. Protective responses in the ischemic myocardium. J Clin Invest 2000; 106:813–818.
78. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994; 90:II228–II234.
79. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5:434–438.
80. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298–307.
81. Hershey JC, Baskin EP, Glass JD, et al. Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc Res 2001; 49:618–625.
82▪▪. Wen J, Zhang JQ, Huang W, Wang Y. SDF-1alpha and CXCR4 as therapeutic targets in cardiovascular disease. Am J Cardiovasc Dis 2012; 2:20–28.
Here the authors describe in detail the role of the CXCL12/CXCR4 axis and its antagonists in cardiovascular diseases. In particular, they focus on the involvement of CXCR4 in the steps of cell homing/trafficking, and injury/tissue repair.
83. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003; 107:1322–1328.
84. Zaruba MM, Franz WM. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin Biol Ther 2010; 10:321–335.
85▪▪. Luo Y, Zhao X, Zhou X, et al. Short-term intermittent administration of CXCR4 antagonist AMD3100 facilitates myocardial repair in experimental myocardial infarction. Acta Biochim Biophys Sin (Shanghai) 2013; 45:561–569.
This study demonstrated the pivotal role of AMD3100 as CXCR4 antagonist in ischemia/reperfusion injury. Administration of AMD3100 prolongs bone marrow progenitor mobilization and improves the recovery from injury, which illustrates the putative role of AMD3100 as a therapeutic agent in myocardial infarction.
86▪▪. Jujo K, Ii M, Sekiguchi H, et al. CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation 2013; 127:63–73.
This study demonstrated the pivotal role of AMD3100 as CXCR4 antagonist in ischemia/reperfusion injury. Administration of AMD3100 prolongs bone marrow progenitor mobilization and improves the recovery from injury, which illustrates the putative role of AMD3100 as a therapeutic agent in myocardial infarction.
87. Toupadakis CA, Wong A, Genetos DC, et al. Long-term administration of AMD3100, an antagonist of SDF-1/CXCR4 signaling, alters fracture repair. J Orthop Res 2012; 30:1853–1859.
88. Maharaj SS, Baroke E, Gauldie J, Kolb MR. Fibrocytes in chronic lung disease: facts and controversies. Pulm Pharmacol Ther 2012; 25:263–267.
89. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345:517–525.
90. Selman M, King TE, Pardo A. American Thoracic Society; European Respiratory Society; American College of Chest PhysiciansIdiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136–151.
91. American Thoracic SocietyIdiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646–664.
92. Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166:7556–7562.
93. Yang L, Scott PG, Giuffre J, et al. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest 2002; 82:1183–1192.
94. Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004; 113:243–252.
95. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114:438–446.
96. Andersson-Sjoland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40:2129–2140.
97. Mehrad B, Burdick MD, Zisman DA, et al. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353:104–108.
98. Song JS, Kang CM, Kang HH, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med 2010; 42:465–472.
99▪. Makino H, Aono Y, Azuma M, et al. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J Med Invest 2013; 60:127–137.
Administration of AMD3100 directly inhibited the migration of human fibrocytes in response to CXCL12 in vitro, and reduced the trafficking of fibrocytes into the lungs treated with bleomycin in vivo. The results of this study suggest that the blockade of CXCR4 might be a useful strategy for therapy of patients with pulmonary fibrosis due to the inhibition of the migration of circulating fibrocytes.
CXCL12/CXC chemokine receptor type 4 axis; CXC chemokine receptor type 4 antagonist; plerixafor (AMD3100)
© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
Highlight selected keywords in the article text.